You are here

Session on Haematologic Toxicities: anemia therapies and EORTC recommendations

By Pere Gascón, recorded at TAO (Transatlantic Oncology meeting), Nov 20-21, 2014, Paris

25- Père Gascon ANG

Pere Gascón speaks about the EORTC guidelines for the use of erythropoietic proteins in anemic patients with cancer. He reviews the 2011 position of the EORTC Working Party in comparison to the 2006 and 2007 EORTC guideline updates as well as the ASCO/ASH, NCCN and ESMO guidelines. The major goals of erythropoiesis-stimulating agents (ESA) are the prevention of transfusions and the improvement of quality of life. According to the 2011 position of the EORTC Working Party, ESA therapy decreases transfusion needs, ensures better maintenance of Hb levels than intermittent transfusions, improves quality of life in patients with chemotherapy-induced anemia and should be used within the guidelines. Prophylactic use of erythropoietic proteins to prevent anemia in patients who undergo chemo- and/or radiotherapy and have normal Hb values at the start of treatment is not recommended.


Pere Gascón, Hospital Clinic de Barcelona, Spain

Search this site

Featured videos

Free access to ebooks on cachexia and CINV


Prevention of nausea and vomiting in
adult cancer patients receiving tumour-
directed therapy – 2017 update –

Cancer cachexia: mechanisms and progress in treatment


Stay up-to-date with our monthly e-alert

If you want to regularly receive information on what is happening in Quality of Life in Oncology research sign up to our e-alert.

Subscribe »

QOL (Quality of Life) newsletter e-alert

Quality of Life promotional video

Made possible by an educational grant from Helsinn

Helsinn does not have any influence on the content and all items are subject to independent peer and editorial review

Society Partners

European Cancer Organisation Logo